Prelude Therapeutics (PRLD) Change in Account Payables (2019 - 2026)

Prelude Therapeutics has reported Change in Account Payables for 8 years, with the latest figure at -$1.9 million in Q1 2026.

• Quarterly Change in Account Payables rose 1.62% year-over-year to -$1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.9 million (down 608.77% YoY) and the FY2025 annual result came in at -$3.9 million, down 218.55% from the prior year.
• Change in Account Payables eased to -$1.9 million in Q1 2026 per PRLD's latest filing, from $1.3 million in the prior quarter.
• Over five years, Change in Account Payables peaked at $3.7 million in Q3 2022 and troughed at -$3.2 million in Q4 2022.
• A 5-year average of -$300529.4 and a median of -$465000.0 in 2023 frame the typical range for Change in Account Payables.
• The sharpest annual moves came in 2023 and 2025: Change in Account Payables soared 18600.0% in 2023, then tumbled 1040.38% in 2025.
• Over 5 years, Change in Account Payables stood at -$3.2 million in 2022, then soared by 85.65% to -$465000.0 in 2023, then soared by 489.25% to $1.8 million in 2024, then fell by 29.78% to $1.3 million in 2025, then slumped by 247.84% to -$1.9 million in 2026.
• According to Business Quant data, Change in Account Payables over the past three periods registered -$1.9 million, $1.3 million, and -$2.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.